Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.
An article from
Emerging biotech
Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.
Published June 3, 2026
An Eli Lilly logo is seen on the side of a building in November 2021.
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics
Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations - Eli Lilly (NYSE:LLY)
Camurus announces expansion of Lilly collaboration
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Legend Biotech emerged as a rare market winner
Lilly, Hanmi sign $1.26bn licensing deal for sonefpeglutide
Post-Hoc: The world's biggest drugmaker get more secretive
A turning point for pancreatic cancer patients
ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma
Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now…
The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering…
Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an…
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion…
GLP-1 riches are being repurposed to prevent infections.
